News

We are excited to announce that Neurim Pharmaceuticals received a positive CHMP opinion on Slenyto® (Pediatric Prolonged-Release Melatonin) for the treatment of Insomnia in children with Neurogenetic Disorders (NGDs). This […]

Neurim Pharmaceuticals is attending IPSA 2024 Congress in Glasgow. We are delighted to invite IPSA 2024 attendees to participate in our satellite symposium “Advances in treatment of insomnia in children […]

We were thrilled to gather our international partners once more for a successful meeting focused on exchanging ideas and insights, all with the goal of promoting improved care for children […]

Neurim and partners are delighted to participate in ESCAP 2023 aiming to increase awareness for Insomnia in children with ASD.

We were delighted to have our international partners together, for another successful meeting, sharing ideas and insights, aiming at promoting better care of insomnia in children with ASD.

We are delighted to invite ESCAP 2022 attendees to participate in our satellite symposium “Screen, Evaluate and Treat Insomnia in Children with ASD” on Monday, June 20th at 12:30. Symposium […]

We held our Annual Partners’ Meeting with our international colleagues, sharing insights and ideas for better care of insomnia in ASD children.      

We are excited to announce that as of March Slenyto is also available in Spain for the treatment of insomnia in children with ASD.

We are delighted to invite WSC 2022 attendees to participate in our satellite symposium “Advances in insomnia in ASD- from research to clinical practice” on Monday, March 14th at 12:30. […]